The immunomodulatory effect of Sambucol on leishmanial and malarial infections

Planta Medica

Volumn 75, Issue 6, 2009, Pages 581-586

  Waknine Grinberg, Judith Hannah ^a,c   El On, Joseph ^b   Barak, Vivian ^a   Barenholz, Yechezkel ^c   Golenser, Jacob ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

Cytokines; Immunomodulation; Leishmaniasis; Malaria; Sambucol; Sambucus nigra L. (Sambucaceae)

Indexed keywords

AMPHOTERICIN B DERIVATIVE; ANTILEISHMANIAL AGENT; ANTIMALARIAL AGENT; ARTEMISIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; SAMBUCOL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; BRAIN MALARIA; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOMODULATION; IN VIVO STUDY; INFECTION PREVENTION; LEISHMANIA MAJOR; LEISHMANIASIS; MONONUCLEAR CELL; MOUSE; NONHUMAN; PLASMODIUM BERGHEI INFECTION; RAT; SYMPTOM;

ANIMALS; ANTIMALARIALS; ANTIPROTOZOAL AGENTS; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; LEISHMANIASIS; MALARIA; MALARIA, CEREBRAL; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MONOCYTES; PHYTOTHERAPY; PLANT EXTRACTS; PLASMODIUM BERGHEI; SAMBUCUS; TH1 CELLS;

MURINAE; MUS; PLASMODIUM BERGHEI; SAMBUCUS NIGRA;

EID: 68949083821     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1185357     Document Type: Article

References (30)

1. Jones TC. Immunomodulation - an idea from the past looks more promising than ever. Braz J Infect Dis 2001; 5: 233-234
2. Ramos-Avila A, Ventura-Gallegos JL, Zentella-Dehesa A, Machuca-Rodríguez C, Moreno-Altamirano MM, Narváez V, Legorreta-Herrera M. Immunomodulatory role of chloroquine and pyrimethamine in Plasmodium yoelii 17XL infected mice. Scand J Immunol 2007; 65: 54-62 (Pubitemid 44968072)
3. Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 2008; 2: 109-126
4. Mansueto P, Vitale G, Di Lorenzo G, Rini GB, Mansueto S, Cillari E. Immunopathology of leishmaniasis: an update. Int J Immunopathol Pharmacol 2007; 20: 435-445
5. Hunt NH, Golenser J, Chan-Ling T, Parekh S, Rae C, Potter S, Medana IM, Miu J, Ball HJ. Immunopathogenesis of cerebral malaria. Int J Parasitol 2006; 36: 569-582
6. Malaguarnera L, Musumeci S. The immune response to Plasmodium falciparum malaria. Lancet Infect Dis 2002; 8: 472-478 (Pubitemid 34826852)
7. Binka FN, Morris SS, Ross DA, Arthur P, Aryeetey ME. Patterns of malaria morbidity and mortality in children in northern Ghana. Trans R Soc Trop Med Hyg 1994; 4: 381-385 (Pubitemid 24264515)
8. Elhassan IM, Hviid L, Jakobsen PH, Giha H, Satti GM, Arnot DE, Jensen JB, Theander TG. High proportion of subclinical Plasmodium falciparum infections in an area of seasonal and unstable malaria in Sudan. Am J Trop Med Hyg 1995; 53: 78-83
9. Mayanja-Kizza H. Clinical expression of malaria: why Mary and not John. Malaria Infection in Africa 1995; 2: 26-30
10. Modiano D, Petrarca V, Sirima BS, Nebie I, Diallo D, Esposito F, Coluzzi M. Different response to Plasmodium falciparum malaria in west African sympatric ethnic groups. Proc Natl Acad Sci 1996; 93: 13206-13211 (Pubitemid 26382794)
11. Bradley DJ, Taylor BA, Blackwell J, Evans EP, Freeman J. Regulation of Leishmania populations within the host III. Mapping of the locus controlling susceptibility to visceral leishmaniasis in the mouse. Clin Exp Immunol 1979; 37: 7-14
12. Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva Lde A, Rabello A, Teixeira-Carvalho A, Ferrari TC, Correa-Oliveira R. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand J Immunol 2005; 5: 487-495 (Pubitemid 41719325)
13. Sacks DL, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2: 845-858 (Pubitemid 37328707)
14. Soares Rocha FJ, Schleicher U, Mattner J, Alber G, Bogdan C. Cytokines, signaling pathways, and effector molecules required for the control of Leishmania (Viannia) braziliensis in mice. Infect Immun 2007; 75: 3823-3832 (Pubitemid 47206279)
15. Golenser J, McQuillan J, Hee L, Mitchell AJ, Hunt NH. Conventional and experimental treatment of cerebral malaria. Int J Parasitol 2006; 36: 583-593 (Pubitemid 43674518)
16. von Stebut E, Udey MC. Requirements for Th1-dependent immunity against infection with L. major. Microbes Infect 2004; 6: 1102-1109 (Pubitemid 39233683)
17. Chan MM, Adapala NS, Fong D. Curcumin overcomes the inhibitory effect of nitric oxide on Leishmania. Parasitol Res 2005; 96: 49-56 (Pubitemid 40674924)
18. Park AY, Hondovicz B, Kopf M, Scott P. The role of IL-12 in maintaining resistance to Leishmania major. J Immunol 2002; 168: 5771-5777 (Pubitemid 34556162)
19. Rocha FJ, Schleicher U, Mattner J, Alber G, Bogdan C. Cytokines, signaling pathways, and effector molecules required for the control of Leishmania (Viannia) braziliensis in mice. Infect Immun 2007; 8: 3823-3832 (Pubitemid 47206279)
20. Zimmermann S, Dalpke A, Heeg K. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections. Int J Med Microbiol 2008; 298: 39-44 (Pubitemid 350216549)
21. Barak V, Birkenfeld S, Halperin T, Kalickman I. The effect of herbal remedies on the production of human inflammatory and anti-inflammatory cytokines. Isr Med Assoc J 2002; 4: 919-922 (Pubitemid 35291271)
22. Zakay-Rones Z, Varsano N, Zlotnik M, Manor O, Regev L, Schlesinger M, Mumcuoglu M. Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (Sambucus nigra L.) during an outbreak of influenza B Panama. J Altern Complement Med 1995; 1: 361-369
23. Alberte RS, Gow RT, Sypert GW, Li D. Extractions and methods comprising elder species. Patent application. Available at: http://appft1.uspto. gov. Accessed June 20, 2008
24. Golenser J, Frankenburg S, Ehrenfreund T, Domb AJ. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob Agents Chemother 1999; 43: 2209-2214 (Pubitemid 29421202)
25. Avnir Y, Ulmansky R,Wasserman V, Even-Chen S, Broyer M, Barenholz Y, Naparstek Y. Amphipathic weak acid glucocorticoid prodrugs remoteloaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheum 2008; 58: 119-129
26. Waknine-Grinberg JH, Barenholz Y, Barhum K, Avnir Y, Haynes RK, Golenser J. Glucocorticosteroids encapsulated in sterically stabilized nano-liposomes are therapeutically efficacious against murine cerebral malaria. (In preparation)
27. Barak V, Halperin T, Kalickman I. The effect of Sambucol, a black elderberry- based, natural product, on the production of human cytokines: I. Inflammatory cytokines. Eur Cytokine Netw 2001; 12: 290-296
28. Aguilar-Torrentera F, Carlier Y. Immunological factors governing resistance and susceptibility ofmice to Leishmania major infection. Rev Latinoam Microbiol 2001; 43: 135-142 (Pubitemid 37051514)
29. Hunt N, Grau G. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol 2003; 24: 491-499 (Pubitemid 37088152)
30. Nie CQ, Bernard NJ, Schofield L, Hansen DS. CD4+ CD25+ regulatory T cells suppress CD4+ T-cell function and inhibit the development of Plasmodium berghei-specific TH1 responses involved in cerebral malaria pathogenesis. Infect Immun 2007; 75: 2275-2282 (Pubitemid 46744315)